文献速递妇科肿瘤

宫颈癌术中淋巴结转移放弃根治性子宫切除不劣于完成手术

Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study.
PubMed 文献 · Eur J Cancer · 2020-12-05

ABRAX国际回顾性队列纳入515例宫颈癌(IA-IIB期)术中检出淋巴结转移患者,比较完成根治性子宫切除(COMPL组361例)与放弃子宫手术(ABAND组154例)的生存差异。结果显示两组无进展生存、盆腔复发及总生存均无显著差异,完成根治性子宫切除未带来生存获益,术中确认淋巴结转移者可考虑放弃子宫根治性手术并直接行根治性放化疗。

要点

  • 术中检出淋巴结转移的宫颈癌患者,完成根治性子宫切除未改善无进展生存。
  • 两组复发、盆腔复发及死亡风险均无显著差异,无亚组显示生存获益。
  • 术中确认淋巴结转移者可考虑放弃子宫根治性手术,转行根治性放化疗。

核心结论

  • 宫颈癌术中检出淋巴结转移者,完成根治性子宫切除未改善生存,可考虑放弃子宫手术并直接行根治性放化疗。

研究设计与样本

  • ABRAX国际回顾性队列研究,纳入19国51家机构2005-2015年515例IA-IIB期宫颈癌术中淋巴结转移患者。
  • 按计划子宫手术是否完成分为COMPL组(N=361)与ABAND组(N=154),比较无进展生存。
  • ABAND组92.9%接受根治性放化疗,COMPL组91.4%接受辅助放化疗或化疗。

主要发现

  • 两组复发风险(HR 1.154,95%CI 0.799-1.666,P=0.45)无显著差异。
  • 两组盆腔复发风险(HR 0.836,95%CI 0.458-1.523,P=0.56)无显著差异。
  • 两组死亡风险(HR 1.064,95%CI 0.690-1.641,P=0.78)无显著差异。
  • 无亚组显示完成根治性子宫切除带来生存获益。
  • 中位随访58个月,无病生存率74%(381/515);FIGO分期和盆腔淋巴结转移数目为显著预后因素。

临床怎么用

  • 术中确认淋巴结转移时,可考虑放弃子宫根治性手术,将患者转诊行根治性放化疗。

局限性

  • 回顾性研究设计,非随机分组,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of cervical cancer patients with intraoperative detection of lymph node involvement remains controversial. Since all these patients are referred for (chemo)radiation after the surgery, the key decision is whether radical hysterectomy should be completed as originally planned, taking into account an additional morbidity associated with extensive surgical dissection prior to adjuvant treatment. The ABRAX study investigated whether completing a radical uterine procedure is associated with an improved oncological outcome of such patients. PATIENTS AND METHODS: We performed retrospective analyses of 515 cervical cancer patients (51 institutions, 19 countries) who were referred for primary curative surgery between 2005 and 2015 (stage IA-IIB, common tumour types) in whom lymph node involvement was detected intraoperatively. Patients were stratified according to whether the planned uterine surgery was completed (COMPL group, N = 361) or abandoned (ABAND group, N = 154) to compare progression-free survival. Definitive chemoradiation was given to 92.9% patients in the ABAND group and adjuvant (chemo)radiation or chemotherapy to 91.4% of patients in the COMPL group. RESULTS: The risks of recurrence (hazard ratio [HR] 1.154, 95% confidence intervals [CI] 0.799-1.666, P = 0.45), pelvic recurrence (HR 0.836, 95% CI 0.458-1.523, P = 0.56), or death (HR 1.064, 95% CI 0.690-1.641, P = 0.78) were not significantly different between the two groups. No subgroup showed a survival benefit from completing radical hysterectomy. Disease-free survival reached 74% (381/515), with a median follow-up of 58 months. Prognostic factors were balanced between the two groups. FIGO stage and number of pelvic lymph nodes involved were significant prognostic factors in the whole study cohort. CONCLUSION: We showed that the completion of radical hysterectomy does not improve survival in patients with intraoperatively detected lymph node involvement, regardless of tumour size or histological type. If lymph node involvement is confirmed intraoperatively, abandoning uterine radical procedure should be considered, and the patient should be referred for definitive chemoradiation. CLINICAL TRIALS IDENTIFIER: NCT04037124.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cibula D, Dostalek L, Hillemanns P, et al. Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. Eur J Cancer. 2020. PMID: 33290995. doi:10.1016/j.ejca.2020.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。